SETTLEMENT AND TERMINATION AGREEMENTSettlement and Termination Agreement • June 4th, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS SETTLEMENT AND TERMINATION AGREEMENT (“Termination Agreement”) dated as of October 8, 2012 (“Execution Date”), is entered into between Revance Therapeutics, Inc., a Delaware corporation having its principal place of business at 7555 Gateway Blvd., Newark, CA 94560 (“Revance”) and Medicis Pharmaceutical Corporation, a Delaware corporation with offices at 7720 North Dobson Road, Scottsdale, AZ 85256 (“Medicis”).
ContractDevelopment, Manufacturing and Supply Agreement • June 4th, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations
[ ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
MANUFACTURE AND DEVELOPMENT AGREEMENTManufacture and Development Agreement • June 4th, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
This Manufacture and Development Agreement (the “Agreement”) is entered into as of 20 MAY 2013 (the “Effective Date”), by and between REVANCE THERAPEUTICS, INC., (“Revance”), located at 7555 Gateway Boulevard, Newark, CA 94560 and AMERICAN PEPTIDE COMPANY, INC., (“APC”), located at 777 E. Evelyn Avenue, Sunnyvale, CA 94086. References to “Revance” and “APC” shall include their respective Affiliates.
REVANCE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • June 4th, 2013 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 29th day of March, 2013, by and among REVANCE THERAPEUTICS, INC., a Delaware corporation (the “Company”) and certain of the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
